Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: Assistant General Manager
Company: Junshi Biosciences
个人简介:
Mr. Yu is the assistant general manager of Junshi Biosciences, in charge of investment and financing. He is a core member of company’s financing projects like HKEX listing, SSE STAR Market listing and refinancing. Currently, he is mainly responsible for the company's investor communication, equity financing, and external Investment related businesses. Before joining Junshi, Mr. Yu has more than 12 years of experience in the financial industry. He previously held positions in Zhonghai Fund, Changjiang Securities, GF Securities and Everbright Securities. He also won Crystal Ball Sell-Side Analysts Awards and the Best Analyst of New Fortune for many times, with many excellent research projects selected by the SZSE and the SAC.
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: Chief Investment Officer
Company: Simcere Pharmaceutical
个人简介:
Mr. Zhou Gaobo, the Chief Investment Officer of Simcere Pharmaceutical Group (2096.HK). He is in charge of the company's innovative drug investment and business development, establishment of new investment platforms, as well as the investment strategy planning and practice.Before joining Simcere, Mr. Gaobo Zhou was a Partner at McKinsey & Company and co-leader of the Greater China Healthcare practice. He has fifteen years of experience in management consulting in the healthcare industry. He worked with leading pharmaceutical, biotechnology, medical device, and life science investment companies on a broad range of topics in China Healthcare Reform and innovation, including strategy, business model innovation, digital transformation, and investment and partnership. He also built the largest healthcare management consulting team in the industry. Previously, he also worked at Human Genome Sciences (HGSI) in antibody and fusion protein drug development.Mr. Gaobo Zhou holds an MBA from Duke University, a Master's Degree in Biochemistry from the University of Maryland and a Bachelor’s Degree in Genetics from Fudan University.
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: General Manager
Company: Shanghai Huaota Biopharmaceutical Co., Ltd
个人简介:
Dr. Zhu is an expert in antibody drug discovery and process development with more than 18 years of industrial experience. He has extensive experience in antibody drug discovery, process development, and manufacture facility construction. Dr. Zhu is the CEO for both Huaota Biopharm and Huabo Biopharm (members of Huahai Pharm), leads its global biotherapeutic research. Prior to join Huahai, he worked at Boehringer Ingelheim for more than 8 years in different function areas at multiple locations ( Ridgefield, USA; Biberach, Germany; and Shanghai, China). He led and engaged in over 20 global BI biological research projects including current clinic Phase I-III projects and market products; Dr. Zhu obtained his PhD in microbiology and immunology from the University of Illinois at Chicago .
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: Head of Roche Pharma Partnering Asia
Company: Roche
个人简介:
Harm-Jan Borgeld, Head of Roche Pharma Partnering Asia is responsible for the negotiations of innovative, Asia sourced, deals to transform R&D strategic wants into global research and development plans to improve Roche’s external innovation portfolio with first in-class and best in-class compounds. Harm-Jan is based in Shanghai and is a member of the Leadership Team of Roche Pharma Partnering.Having grown up in the Netherlands, had various careers and roles in the army, academia and pharmaceutical industry. He graduated in 1993 from Wageningen University, his passion was biochemistry and business administration.He received 6 honors and awards, including 1st prize winner in McKinsey 2001 Business Plan Competition, Netherlands, and an award for Excellent Leadership as Lieutenant in the Dutch Army.He conducted his PhD research at the Faculty of Medicine, Nagoya University in Nagoya, Japan in 1995 before finishing his Postdoctoral fellowship of Research Institute from Institute of Applied BioTechnology. His focus area was mitochondrial gene therapy, where he developed a novel approach to selectively remove mutated DNA from the mitochondria and creating a possible pathway for treatment options for patients. In 2001 he moved to the Netherlands for his MBA at Rotterdam School of Management, in 2002 to the US to study for his MBA at the Haas Business School. He graduated in 2003.In 2003, he joined Kyorin Pharmaceuticals, in Germany, as Head BD where he negotiated 3 deals and created 2 business plans for the region Europe.He spent most of his career at Merck Healthcare KGaA, over 15 years in various positions, he started in 2005 as Senior Licensing Manager in Business Development. In 2008 he became Global Project Team Leader, where he led the clinical development of an immune-oncology antibody. From 2010 he was the Vice President, Head Global Alliance Management. His group oversaw 110-120 global alliances in Research, Development, Commercial and 15-20 regional alliances in Latin America.